Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Baraldi

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Cephalalgia : an International Journal of Headache|February 9, 2022
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headacheUmberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
The Journal of Headache and Pain|September 12, 2018
The association between migraine and physical exerciseFaisal Mohammad Amin, Stavroula Aristeidou, Carlo Baraldi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2021
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headacheUmberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
Journal of Neurology|July 19, 2023
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO studyFabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
Cephalalgia : an International Journal of Headache|April 26, 2022
Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot studyPierangelo Geppetti, Francesco De Cesaris, Silvia Benemei, et al.
International Journal of Environmental Research and Public Health|September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different PredictorsRaffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Pain and Therapy|March 29, 2021
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter StudyRaffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Pain and Therapy|September 26, 2021
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 PatientsRaffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 20, 2023
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ)Agnese Onofri, Luigi Francesco Iannone, Antonio Granato, et al.
CNS Drugs|November 24, 2023
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort StudyValeria Caponnetto, Antonio Russo, Marcello Silvestro, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Cephalalgia : an International Journal of Headache|February 9, 2022
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headacheUmberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
The Journal of Headache and Pain|September 12, 2018
The association between migraine and physical exerciseFaisal Mohammad Amin, Stavroula Aristeidou, Carlo Baraldi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2021
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headacheUmberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
Journal of Neurology|July 19, 2023
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO studyFabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
Cephalalgia : an International Journal of Headache|April 26, 2022
Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot studyPierangelo Geppetti, Francesco De Cesaris, Silvia Benemei, et al.
International Journal of Environmental Research and Public Health|September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different PredictorsRaffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Pain and Therapy|March 29, 2021
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter StudyRaffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Pain and Therapy|September 26, 2021
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 PatientsRaffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 20, 2023
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ)Agnese Onofri, Luigi Francesco Iannone, Antonio Granato, et al.
CNS Drugs|November 24, 2023
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort StudyValeria Caponnetto, Antonio Russo, Marcello Silvestro, et al.
Pageof 6